{"protocolSection":{"identificationModule":{"nctId":"NCT04256473","orgStudyIdInfo":{"id":"DUMAS-1.1"},"organization":{"fullName":"Erasmus Medical Center","class":"OTHER"},"briefTitle":"Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke","officialTitle":"Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke","acronym":"DUMAS"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-08-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-03-26","type":"ACTUAL"},"completionDateStruct":{"date":"2022-05-26","type":"ACTUAL"},"studyFirstSubmitDate":"2020-02-03","studyFirstSubmitQcDate":"2020-02-04","studyFirstPostDateStruct":{"date":"2020-02-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-05","lastUpdatePostDateStruct":{"date":"2023-09-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Nadinda van der Ende","investigatorTitle":"PI: Prof. Dr. DWJ Dippel and A. van der Lugt","investigatorAffiliation":"Erasmus Medical Center"},"leadSponsor":{"name":"Erasmus Medical Center","class":"OTHER"},"collaborators":[{"name":"DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV infusion of mutant pro-urokinase against usual treatment with IV alteplase in patients presenting with ischemic stroke."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["Randomized Controlled Trial","Thrombolytic treatment","Intracranial hemorrhage","Mutant pro-urokinase","Ischemic stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":200,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention","type":"EXPERIMENTAL","description":"Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.\n\nDepending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes).","interventionNames":["Drug: mutant pro-urokinase"]},{"label":"Control","type":"ACTIVE_COMPARATOR","description":"Usual care with alteplase 0.9 mg/kg in 60 minutes","interventionNames":["Drug: Alteplase"]}],"interventions":[{"type":"DRUG","name":"mutant pro-urokinase","description":"Intravenous administration","armGroupLabels":["Intervention"],"otherNames":["HisproUK"]},{"type":"DRUG","name":"Alteplase","description":"Intravenous administration","armGroupLabels":["Control"],"otherNames":["Actilyse"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Any intracranial hemorrhage according to the Heidelberg Bleeding Classification on MRI","timeFrame":"24-48 hours post-treatment"}],"secondaryOutcomes":[{"measure":"Score on the National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS measures neurological deficit, ranging from 0 to 42, with higher scores indicating more severe neurological deficit.","timeFrame":"at 24 hours and 5-7 days post-treatment"},{"measure":"Score on the modified Rankin Scale (mRS)","description":"The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death) measuring the degree of disability or dependence in everyday life.","timeFrame":"at 30 days"},{"measure":"Infarct volume on MRI","timeFrame":"at 24-48 hours"},{"measure":"Change (pre-treatment vs. post-treatment) in abnormal perfusion volume based on TTP/MTT maps measured with CT perfusion at baseline and MRI","timeFrame":"at 24-48 hours post treatment."},{"measure":"Secondary blood biomarkers of thrombolysis: d-dimer levels and fibrinogen levels.","timeFrame":"1 hour post-treatment, after 3 hours, and after 24 hours post-treatment,"},{"measure":"Symptomatic intracranial hemorrhage (sICH) according to the Heidelberg Bleeding Classification","description":"sICH is defined as any intracranial hemorrhage followed by a neurological deterioration that can be attributed to that hemorrhage, defined as an increase of \\>= 4 points on the NIHSS or \\>= 2 points on a specific NIHSS item.","timeFrame":"within 30 days"},{"measure":"Death from any cause","timeFrame":"Within 30 days"},{"measure":"Major extracranial hemorrhage according to the ISTH criteria","timeFrame":"within 24 hours of study drug administration"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of ischemic stroke;\n* A score of at least 1 on the NIH Stroke Scale;\n* CT ruling out intracranial hemorrhage;\n* Treatment possible within 4.5 hours from symptom onset or last seen well;\n* Meet the criteria for standard treatment for IV alteplase according to national guidelines27;\n* Age of 18 years or older;\n* Written informed consent (deferred).\n\nExclusion Criteria:\n\n* Candidate for endovascular thrombectomy (i.e., a proximal intracranial large artery occlusion on CTA);\n* Contra-indication for treatment with IV alteplase according to national guidelines27:\n\n  * Arterial blood pressure exceeding 185/110 mmHg and not responding to treatment\n  * Blood glucose less than 2.7 or over 22.2 mmol/L\n  * Cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging\n  * Head trauma in the previous 4 weeks\n  * Major surgery or serious trauma in the previous 2 weeks\n  * Gastrointestinal or urinary tract hemorrhage in the previous 2 weeks\n  * Previous intracerebral hemorrhage\n  * Use of anticoagulant with INR exceeding 1.7 or APTT exceeding 50 seconds\n  * Known thrombocyte count less than 90 x 109 /L\n  * Treatment with direct thrombin or factor X inhibitors, unless specific antidotum has been given, i.e. idarucizumab in case of dabigatran use.\n* Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS \\> 2;\n* Known pregnancy or if pregnancy cannot be excluded, i.e. did not have intercourse for \\> 6 months and no clinical signs of pregnancy, adequate use of any contraceptive method (e.g. intrauterine devices) or sterilization of the subject herself.\n* Contra-indication for an MRI scan, i.e.:\n\n  * an MRI incompatible pacemaker, ICD, pacing wires and loop records\n  * metallic foreign bodies (e.g. intra-ocular)\n  * prosthetic heart valves\n  * blood vessel clips, coils or stents\n  * an implanted electronic and/or magnetic implant or pump (e.g. neurostimulator)\n  * cochlear implants\n  * mechanical implants (implanted less than 6 weeks ago)\n  * a copper intrauterine device\n* Current Participation in any medical or surgical therapeutic trial other than DUMAS.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"DUMAS trial office","city":"Rotterdam","zip":"3000 CA","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}}]},"referencesModule":{"references":[{"pmid":"35945566","type":"DERIVED","citation":"van der Ende NAM, Roozenbeek B, Smagge LEM, Luijten SPR, Aerden LAM, Kraayeveld P, van den Wijngaard IR, Lycklama A Nijeholt GJ, den Hertog HM, Flach HZ, Wallace AC, Gurewich V, Del Zoppo GJ, Meurer WJ, Lingsma HF, van der Lugt A, Dippel DWJ; DUMAS Investigators. Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial. Trials. 2022 Aug 9;23(1):641. doi: 10.1186/s13063-022-06596-z."}],"seeAlsoLinks":[{"label":"DUMAS website","url":"https://dumas-trial.nl/"}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M21803","name":"Intracranial Hemorrhages","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"},{"id":"C000067551","term":"Saruplase"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M250237","name":"Saruplase","asFound":"DCB-BO1202","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}